Parkinson REASON UDIC

The main purpose of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 to participants with Parkinson’s disease. The General University Hospital of Catalonia is the first center in Spain that has been activated for a new and particular phase I trial in Parkinson’s (REASON), which seeks to…

Compartir:

We have reached the first position, in December 2019, in the international inclusion of patients in the trial with sublingual apomorphine and motor blocks in Parkinson. We are also leading the national inclusion of patients in the Clarity AD trial (monoclonal anti-amyloid antibody in early Alzheimer) Finally, in the Graduate trial (monoclonal subcutaneous in Alzheimer)…

Compartir:

  On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated Aducanumab (an anti-alpha synuclein monoclonal antibody) in early Alzheimer’s disease. Efficacy in slowing cognitive impairment was demonstrated (measured with the CDR-SB, MMSE, ADAS-cog and ADCS-ADL scales) and a reduction in amyloid…

Compartir:

Dr. Balaguer of the General University Hospital of Catalonia talks about Alzheimer’s disease  

Compartir:

We are developping a clinical trial  that evaluates the efficacy and safety of an oral medication that inhibits an enzyme released by a dental germ in patients with moderate Alzheimer’s disease. The GAIN trial (code COR388-010) is a phase III clinical trial and we are carrying out in Spain, in the General University Hospital of…

Compartir:

– Dr. Balaguer, scientific director of the UDIC, has directed the course of Coordination and Practical Management of clinical trials in Neurology (module from 5:30 hours). Completed during the LXX Annual Meeting of the Spanish Society of Neurology (Seville, 24 November 2018). – Continue the development of our projects in Parkinson’s disease: anti-alfasinuclein monoclonal antibodies,…

Compartir:

No dude en llamarnos        1-+34 935 656 000